Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Navan Inc. Class A Common Stock (NAVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Navan Inc. Class A Common Stock — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Navan Inc. Class A Common Stock trades at $23.66 (market cap $6.25B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 4.9× Navan Inc. Class A Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Navan Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| GEHC | NAVN | |
|---|---|---|
Market Cap | $30.93B | $6.25B |
Volume | 5,033,451 | 2,778,133 |
Sector | Health | Technology |
52-Week High | $88.16 | $30.58 |
52-Week Low | $59.48 | $8.51 |
Enterprise Value | $39.39B | $5.60B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 6 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →
